Document Type : Original Article

Authors

1 Faculty of Medicine, Tanta University, Egypt

2 Factuly of Science, Tanta University, Egypt

3 Factuly of Pharmacy, Tanta University, Egypt

4 Preventive and Restorative Dentistry Department, College of Dental Medicine, University of Sharjah, United Arab Emirates / Biomaterials Department, Faculty of Dentistry, Tanta University, Egypt / UCL Eastman Dental Institute, Biomaterials & Tissue Engineering, Royal Free Hospital, Rowland Hill Street, London, UK

Abstract

Background and aims: The coronavirus disease 2019 (COVID-19) is an emerging transmissible infection that can be prevented by proper hygiene measures and vaccination. With the rise and rapid spread of the Omicron variant, vaccines are currently the best protective measure. This cross-sectional study aimed to assess knowledge, practice, and attitude towards COVID-19 virus and vaccines, particularly Sinopharm, among medical students in Mansoura University, Egypt, from July to September 2021.
 
Methods: A cross-sectional study was conducted using a 35-item questionnaire covering demographic data. COVID-19 knowledge/practice and knowledge/attitude towards vaccines were distributed on medical students’ university Facebook group. A score was calculated for knowledge (KS), practice (PS), and attitude (AS). A 60% cutoff was considered satisfactory, and the statistical analysis was carried out using one-way ANOVA, linear regression, and Pearson’s coefficient.
 
Results: A total of 837 students participated in this study. The majority (73.12%) of participants showed satisfactory COVID-19 KS and Sinopharm AS (54.77%) but unsatisfactory PS (68.99%) and Sinopharm KS (62.75%). Knowledge had a significant effect on Sinopharm vaccine acceptance. Moreover, females indicated higher COVID-19 KS and PS, whilst males showed higher Sinopharm KS and AS. Gender and year group had a strong correlation with PS. Furthermore, the majority (92.4%) accepted vaccination and believed it should be mandatory (80.41%). The selected vaccines were Pfizer (44.84%) > AstraZeneca (33.86%) > Sinopharm (15.56%) > others. Efficacy, safety, and country of production were the main predictors of vaccine choice. More than half (59.48%) stated that the country in which the vaccine is produced is important when choosing their intended vaccine, and 20.87% stated that their decision is based on vaccine efficacy.
 
Conclusions: COVID-19 was a challenging pandemic; there are several available COVID-19 vaccines, but the most available in Egypt is the Sinopharm vaccine. The results of this study will provide a basis regarding the knowledge and attitude of medical students who play a crucial part in the cycle of infection. These results will help outline the main causes of misunderstandings that can be solved by providing educational needed interventions, implementing protective measures, and distributing scientifically correct data.

Keywords

1.Adil MT, Rahman R, Whitelaw D, Jain V, Al-Taan O, Rashid F, et al. SARS-CoV-2 and the pandemic of COVID-19. Postgraduate Medical Journal. 2021;97(1144):110-6. 
2.Liu J, Liu S. The management of coronavirus disease 2019 (COVID-19). J Med Virol. 2020;92(9):1484-90. 
3.Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. International Journal of Infectious Diseases. 2020;92:214-7. 
4.Haidere MF, Ratan ZA, Nowroz S, Zaman SB, Jung YJ, Hosseinzadeh H, et al. COVID-19 vaccine: Critical questions with complicated answers. Biomol Ther. 2021;29(1):1-10. 
5.Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40(5):905-19. Epub 2021/01/03. 
6.Awadasseid A, Wu Y, Tanaka Y, Zhang W. Current advances in the development of SARS-CoV-2 vaccines. Int J Biol Sci. 2021;17(1):8-19. 
7.Huang Y, Yang C, Xu X-f, Xu W, Liu S-w. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica. 2020;41(9):1141-9. 
8.Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano. 2020;14(10):12522-37. 
9.Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 2021;54(1):12-6. 
10.Chen P, Mao L, Nassis GP, Harmer P, Ainsworth BE, Li F. Coronavirus disease (COVID-19): The need to maintain regular physical activity while taking precautions. J Sport Health Sci. 2020;9(2):103-4. Epub 2020/02/04. 
11.Ağalar C, Öztürk Engin D. Protective measures for COVID-19 for healthcare providers and laboratory personnel. Turk J Med Sci. 2020;50(SI-1):578-84. 
12.Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713-21. 
13.Rogliani P, Chetta A, Cazzola M, Calzetta L. SARS-CoV-2 neutralizing antibodies: A network meta-analysis across vaccines. Vaccines. 2021;9(3). 
14.Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis. 2021;15(21):00462-X. 
15.Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M, et al. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Invest. 2021;26:1-9. 
16.C.J. Burrell CRH, F.A. Murphy, Fenner and white’s medical virology,, 2016 AP. 
17.Albahri AH, Alnaqbi SA, Alnaqbi SA, Alshaali AO, Shahdoor SM. Knowledge, attitude, and practice regarding COVID-19 among healthcare workers in primary healthcare centers in Dubai: A cross-sectional survey, 2020. Frontiers in Public Health. 2021;9(1080). 
18.Olaimat AN, Aolymat I, Shahbaz HM, Holley RA. Knowledge and information sources about COVID-19 among university students in Jordan: A cross-sectional study. Frontiers in Public Health. 2020;8. 
19.Jain J, Saurabh S, Kumar P, Verma MK, Goel AD, Gupta MK, et al. COVID-19 vaccine hesitancy among medical students in India. Epidemiol Infect. 2021;20(149). 
20.Barello S, Nania T, Dellafiore F, Graffigna G, Caruso R. ‘Vaccine hesitancy’ among university students in Italy during the COVID-19 pandemic. Eur J Epidemiol. 2020;35(8):781-3. Epub 2020/08/06. 
21.Zahid HM, Alsayb MA. Assessing the Knowledge and Attitude toward COVID-19 Vaccination in Saudi Arabia. Int J Environ Res Public Health. 2021;18(15). 
22.Elgendy MO, Abdelrahim MEA. Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy. J Med Virol. 2021;93(12):6535-43. 
23.Acharya SR, Moon DH, Shin YC. Assessing attitude toward COVID-19 vaccination in South Korea. Frontiers in Psychology. 2021;12(3222). 
24.Hani M. Nassar EAAN. Awareness and utilization of bulk-fill composites among dental practitioners in Saudi Arabia. The Open Dentistry Journal. 2021; 15:160-9. 
25.Chan-Yeung M, Xu R-H. SARS: epidemiology. Respirology. 2003;8 Suppl(Suppl 1):S9-S14. 
26.Teo SP. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. J Pharm Pract. 2021;12(897190021100965 0):08971900211009650. 
27.Vanaparthy R, Mohan G, Vasireddy D, Atluri P. Review of COVID-19 viral vector-based vaccines and COVID-19 variants. Infez Med. 2021;29(3):328-38. 
28.Palacios R, Patiño EG, de Oliveira Piorelli R, Conde M, Batista AP, Zeng G, et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (Inactivated) vaccine manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial: Trials. 2020 Oct 15;21(1):853. doi: 10.1186/s13063-020-04775-4. 
29.Sanders B, Koldijk M, Schuitemaker H. Inactivated viral vaccines. Vaccine Analysis: Strategies, Principles, and Control. 2014:45-80. 
30.Dadras O, Alinaghi SAS, Karimi A, MohsseniPour M, Barzegary A, Vahedi F, et al. Effects of COVID-19 prevention procedures on other common infections: a systematic review. European Journal of Medical Research. 2021;26(1):67. 
31.Ophinni Y, Hasibuan AS, Widhani A, Maria S, Koesnoe S, Yunihastuti E, et al. COVID-19 vaccines: Current status and implication for use in Indonesia. Acta Med Indones. 2020;52(4):388-412.